134 related articles for article (PubMed ID: 35984904)
1. Azithromycin promotes relapse by disrupting immune and metabolic networks after allogeneic stem cell transplantation.
Vallet N; Le Grand S; Bondeelle L; Hoareau B; Corneau A; Bouteiller D; Tournier S; Derivry L; Bohineust A; Tourret M; Gibert D; Mayeur E; Itzykson R; Pacchiardi K; Ingram B; Cassonnet S; Lepage P; Peffault de Latour R; Socié G; Bergeron A; Michonneau D
Blood; 2022 Dec; 140(23):2500-2513. PubMed ID: 35984904
[TBL] [Abstract][Full Text] [Related]
2. Effect of Azithromycin on Airflow Decline-Free Survival After Allogeneic Hematopoietic Stem Cell Transplant: The ALLOZITHRO Randomized Clinical Trial.
Bergeron A; Chevret S; Granata A; Chevallier P; Vincent L; Huynh A; Tabrizi R; Labussiere-Wallet H; Bernard M; Chantepie S; Bay JO; Thiebaut-Bertrand A; Thepot S; Contentin N; Fornecker LM; Maillard N; Risso K; Berceanu A; Blaise D; Peffault de La Tour R; Chien JW; Coiteux V; Socié G;
JAMA; 2017 Aug; 318(6):557-566. PubMed ID: 28787506
[TBL] [Abstract][Full Text] [Related]
3. Circulating T cell profiles associate with enterotype signatures underlying hematological malignancy relapses.
Vallet N; Salmona M; Malet-Villemagne J; Bredel M; Bondeelle L; Tournier S; Mercier-Delarue S; Cassonnet S; Ingram B; Peffault de Latour R; Bergeron A; Socié G; Le Goff J; Lepage P; Michonneau D
Cell Host Microbe; 2023 Aug; 31(8):1386-1403.e6. PubMed ID: 37463582
[TBL] [Abstract][Full Text] [Related]
4. Risk of relapse in patients receiving azithromycin after allogeneic HSCT.
Kutzke JL; Merten JA; Taraba JL; Mara KC; Shah MV; Hashmi SK; Patnaik MM; Litzow MR; Hogan WJ; Alkhateeb HB
Bone Marrow Transplant; 2021 Apr; 56(4):960-962. PubMed ID: 33130820
[TBL] [Abstract][Full Text] [Related]
5. Azithromycin Use and Increased Cancer Risk among Patients with Bronchiolitis Obliterans after Hematopoietic Cell Transplantation.
Cheng GS; Bondeelle L; Gooley T; He Q; Jamani K; Krakow EF; Flowers MED; de Latour RP; Michonneau D; Socié G; Chien JW; Chevret S; Bergeron A
Biol Blood Marrow Transplant; 2020 Feb; 26(2):392-400. PubMed ID: 31682980
[TBL] [Abstract][Full Text] [Related]
6. Azithromycin does not increase hematologic relapse in pediatric hematopoietic cell transplant recipients.
Sabulski A; Wallace G; Lane A; Davies SM; Myers KC
Bone Marrow Transplant; 2022 Oct; 57(10):1589-1591. PubMed ID: 35778608
[No Abstract] [Full Text] [Related]
7. Azithromycin for the Treatment of Obliterative Bronchiolitis after Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis.
Yadav H; Peters SG; Keogh KA; Hogan WJ; Erwin PJ; West CP; Kennedy CC
Biol Blood Marrow Transplant; 2016 Dec; 22(12):2264-2269. PubMed ID: 27575542
[TBL] [Abstract][Full Text] [Related]
8. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
9. T-Cell Metabolism in Hematopoietic Cell Transplantation.
Nguyen HD; Kuril S; Bastian D; Yu XZ
Front Immunol; 2018; 9():176. PubMed ID: 29479351
[TBL] [Abstract][Full Text] [Related]
10. [Analysis of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Hematological Malignancies: A Single-center Study].
Lu JP; Wen SP; Wang FX; Li SH; Niu ZY; Wang Y; Zhou ZW; Xu Z; Wang ZZ; Zhang XJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Aug; 30(4):1238-1243. PubMed ID: 35981391
[TBL] [Abstract][Full Text] [Related]
11. Immune Escape of Relapsed AML Cells after Allogeneic Transplantation.
Christopher MJ; Petti AA; Rettig MP; Miller CA; Chendamarai E; Duncavage EJ; Klco JM; Helton NM; O'Laughlin M; Fronick CC; Fulton RS; Wilson RK; Wartman LD; Welch JS; Heath SE; Baty JD; Payton JE; Graubert TA; Link DC; Walter MJ; Westervelt P; Ley TJ; DiPersio JF
N Engl J Med; 2018 Dec; 379(24):2330-2341. PubMed ID: 30380364
[TBL] [Abstract][Full Text] [Related]
12. Allogeneic hematopoietic stem cell transplantation following donor CIK cell infusion: A phase I study in patients with relapsed/refractory hematologic malignancies.
Luo Y; Zeng HQ; Shen Y; Zhang P; Lou SF; Chen L; Deng JC
Leuk Res; 2016 Sep; 48():6-10. PubMed ID: 27416327
[TBL] [Abstract][Full Text] [Related]
13. Allogeneic CD19-CAR-T cell infusion after allogeneic hematopoietic stem cell transplantation in B cell malignancies.
Liu J; Zhong JF; Zhang X; Zhang C
J Hematol Oncol; 2017 Jan; 10(1):35. PubMed ID: 28143567
[TBL] [Abstract][Full Text] [Related]
14. Effect of Sirolimus on Immune Reconstitution Following Myeloablative Allogeneic Stem Cell Transplantation: An Ancillary Analysis of a Randomized Controlled Trial Comparing Tacrolimus/Sirolimus and Tacrolimus/Methotrexate (Blood and Marrow Transplant Clinical Trials Network/BMT CTN 0402).
Gooptu M; Kim HT; Howard A; Choi SW; Soiffer RJ; Antin JH; Ritz J; Cutler CS
Biol Blood Marrow Transplant; 2019 Nov; 25(11):2143-2151. PubMed ID: 31271885
[TBL] [Abstract][Full Text] [Related]
15. TNFR2 blockade of regulatory T cells unleashes an antitumor immune response after hematopoietic stem-cell transplantation.
Moatti A; Debesset A; Pilon C; Beldi-Ferchiou A; Leclerc M; Redjoul R; Charlotte F; To NH; Bak A; Belkacemi Y; Salomon BL; Issa F; Michonneau D; Maury S; Cohen JL; Thiolat A
J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35387779
[TBL] [Abstract][Full Text] [Related]
16. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
[TBL] [Abstract][Full Text] [Related]
17. Metabolic Targets for Improvement of Allogeneic Hematopoietic Stem Cell Transplantation and Graft-vs.-Host Disease.
Tijaro-Ovalle NM; Karantanos T; Wang HT; Boussiotis VA
Front Immunol; 2019; 10():295. PubMed ID: 30891031
[TBL] [Abstract][Full Text] [Related]
18. Improved Overall Survival, Relapse-Free-Survival, and Less Graft-vs.-Host-Disease in Patients With High Immune Reconstitution of TCR Gamma Delta Cells 2 Months After Allogeneic Stem Cell Transplantation.
Minculescu L; Marquart HV; Ryder LP; Andersen NS; Schjoedt I; Friis LS; Kornblit BT; Petersen SL; Haastrup E; Fischer-Nielsen A; Reekie J; Sengelov H
Front Immunol; 2019; 10():1997. PubMed ID: 31507601
[TBL] [Abstract][Full Text] [Related]
19. [Efficacy and safety of IAC regimen for relapse/refractory acute myeloid leukemia: a prospective randomized controlled study].
Li CH; Wei SN; Qiu SW; Gong BF; Gong XY; Li Y; Liu YT; Fang QY; Zhang GJ; Liu KQ; Zhou CL; Lin D; Liu BC; Wang Y; Mi YC; Wei H; Wang JX
Zhonghua Xue Ye Xue Za Zhi; 2022 Apr; 43(4):287-292. PubMed ID: 35680626
[No Abstract] [Full Text] [Related]
20. Preventive azithromycin treatment reduces noninfectious lung injury and acute graft-versus-host disease in a murine model of allogeneic hematopoietic cell transplantation.
Radhakrishnan SV; Palaniyandi S; Mueller G; Miklos S; Hager M; Spacenko E; Karlsson FJ; Huber E; Kittan NA; Hildebrandt GC
Biol Blood Marrow Transplant; 2015 Jan; 21(1):30-8. PubMed ID: 25445642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
